ELI LILLY AND COMPANY Proceeds from Divestiture of Businesses
ELI LILLY AND COMPANY (LLY) reported Proceeds from Divestiture of Businesses of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-02-23.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromDivestitureOfBusinesses · last filed 2022-02-23
- ELI LILLY AND COMPANY proceeds from divestiture of businesses for fiscal 2021 was $0.00.
- ELI LILLY AND COMPANY proceeds from divestiture of businesses for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- ELI LILLY AND COMPANY proceeds from divestiture of businesses for fiscal 2019 was $354.80M.
- ELI LILLY AND COMPANY proceeds from divestiture of businesses for fiscal 2018 was $0.00.
| Period end | Proceeds from Divestiture of Businesses 12 month |
|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-02-23 |
| 2020-12-31 | $0.00 10-K · filed 2022-02-23 |
| 2019-12-31 | $354.80M 10-K · filed 2022-02-23 |
| 2018-12-31 | $0.00 10-K · filed 2021-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |